Previous 10 | Next 10 |
Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET Corporate and Regulatory Highlights Appointment of Richard W. Pascoe as Execut...
OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...
Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmac...
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021, 4:30 p.m. ET CELEBRATION, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development o...
Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and devel...
CELEBRATION, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS ® and serdexmethylphenidate (SDX), the ...
Trading to commence effective with the open of business on October 19, 2021 CELEBRATION, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced&...
The following slide deck was published by KemPharm, Inc. in conjunction with this event. For further details see: KemPharm (KMPH) Investor Presentation - Slideshow
CELEBRATION, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm...
CELEBRATION, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm...
News, Short Squeeze, Breakout and More Instantly...
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Org...
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission...
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:3...